Free shipping on all orders over $ 500

Tiragolumab

Cat. No. M24851

All AbMole products are for research use only, cannot be used for human consumption.

Tiragolumab Structure
Size Price Availability Quantity
100ug USD 150  USD150 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Tiragolumab is an immune checkpoint inhibitor that binds to T-cell immunoglobulin and the structural domain of ITIM (TIGIT), targeting TIGIT with an intact Fc region.TIGIT is a novel inhibitory immune checkpoint expressed primarily on the surface of T-cells and natural killer (NK) cells, which suppresses an organism's immune response to cancer. It can be used in studies related to solid tumors.

Chemical Information
CAS Number 1918185-84-8
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Danielle Brazel, et al. Lung Cancer (Auckl). Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

[2] Gonzalo Recondo, et al. Lancet Oncol. Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer

[3] No authors listed. Cancer Discov. Tiragolumab Results Cast Shadow on TIGIT Pipeline

[4] Peter Sidaway. Nat Rev Clin Oncol. Tiragolumab active in PD-L1+ NSCLC

[5] Byoung Chul Cho, et al. Lancet Oncol. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

Related TIGIT Products
Dargistotug

Dargistotug is a fully human IgG1 monoclonal antibody targeting T-cell immunoglobulin and the ITIM structural domain (TIGIT) that induces an immune response targeting cancer cells by blocking the TIGIT pathway.

Tamgiblimab

Tamgiblimab (IBI939) is a fully human monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). Tamgiblimab has anticancer effects.

Domvanalimab

Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used in research of cancer.

Ociperlimab

Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer.

Vibostolimab

Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research.

  Catalog
Abmole Inhibitor Catalog




Keywords: Tiragolumab supplier, TIGIT, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.